American Society of Hematology

Figure 7.

$Findings confirmed in patients with higher proportion of immature platelets (ITP patients). (A) Platelet indices per donor, including count, mean platelet volume (MPV), flow cytometric forward scatter median fluorescence intensity (MFI), proportion of RNA-rich platelets obtained as in supplemental Figure 5, immature platelet fraction (IPF), and whether donor received thrombopoietin (TPO) receptor agonist. (B-D) Flow cytometric measurements of expression levels of GPVI and HLA-I in resting platelets (B), and PAC1 (C) and CD63 (D) upon stimulation with CRP-XL (5 µg/mL), 2-MeSADP (5 µM), or TRAP-6 (20 µM) per donor. Details on color coding are given in panel A. PAC1 (E) and CD63 (F) expression levels were determined for GPVI-rich (top 25% expressing) platelets and for GPVI-poor (rest of platelets; 75%) platelets for each agonist. Mean ± standard error of mean; n = 2 per group.$

Findings confirmed in patients with higher proportion of immature platelets (ITP patients). (A) Platelet indices per donor, including count, mean platelet volume (MPV), flow cytometric forward scatter median fluorescence intensity (MFI), proportion of RNA-rich platelets obtained as in supplemental Figure 5, immature platelet fraction (IPF), and whether donor received thrombopoietin (TPO) receptor agonist. (B-D) Flow cytometric measurements of expression levels of GPVI and HLA-I in resting platelets (B), and PAC1 (C) and CD63 (D) upon stimulation with CRP-XL (5 µg/mL), 2-MeSADP (5 µM), or TRAP-6 (20 µM) per donor. Details on color coding are given in panel A. PAC1 (E) and CD63 (F) expression levels were determined for GPVI-rich (top 25% expressing) platelets and for GPVI-poor (rest of platelets; 75%) platelets for each agonist. Mean ± standard error of mean; n = 2 per group.

This Feature Is Available To Subscribers Only